19 results about "Phage antibodies" patented technology

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The invention belongs to the technical field of gene engineering and protein engineering, and particularly relates to a fully human antagonistic antibody taking a lactylated STAT6 protein as a target spot and application of the fully human antagonistic antibody. According to the present invention, the completely humanized antagonistic antibody using the lactylated STAT6 protein as the target spot is screened from the human scFv phage antibody library, the amino acid sequence of the completely humanized antagonistic antibody is represented by SEQ ID NO: 1, and the completely humanized antagonistic antibody has the specificity of the targeted lactylated STAT6 protein, and has the application prospect in preparation of the product for diagnosis, treatment or alleviation of sepsis immunosuppression.

The application provides a Mycobacterium tuberculosis EspB monoclonal antibody, a preparation method and application thereof, and relates to the technical field of antibodies. The Mycobacterium tuberculosis EspB monoclonal antibody is obtained by immunizing animals with Mycobacterium tuberculosis cell walls and screening the monoclonal antibody through a phage antibody library technology. The application discloses the Mycobacterium tuberculosis EspB monoclonal antibody or a functional fragment thereof, and application thereof as an antibody conjugate and a composition. The monoclonal antibody has a specific nucleic acid sequence, and codes the specific EspB monoclonal antibody or the functional fragment thereof. The EspB monoclonal antibody obtained by the application has the characteristics of high sensitivity, high specificity and high affinity.

The present application belongs to the technical field of genetic engineering and protein engineering, and particularly relates to a full human source antagonistic antibody with KIAA1199 protein as a target and application thereof; the present application screens a full human source antagonistic antibody (SEQ ID NO:1 or SEQ ID NO:2) with KIAA1199 protein as a target from a human scFv phage antibody library, and respectively determines nucleotide sequences thereof to obtain coding genes thereof; the full human source antagonistic antibody obtained through the method has specificity of targeting KIAA1199 protein, and has application prospects of an inhibitor of targeting KIAA1199 protein or preparation of a drug for treating or relieving inflammatory diseases and / or autoimmune diseases.

The present invention belongs to the field of antibodies, and particularly relates to anti-TNF-α antibodies and their products and applications. The present invention utilizes a canine natural phage antibody library and screens out TNF-α antibodies specific to the specific targets of canine inflammatory bowel disease. ELISA analysis and BLI affinity detection show that the anti-TNF-α antibody can bind to TNF-α. The L929 cytotoxicity experiment demonstrates that the anti-TNF-α antibody has the ability to neutralize the cytotoxicity of this cytokine. By constructing an in vivo TNBS-induced enteritis model, the present invention finds that this antibody can have a good therapeutic effect in treating diseases related to TNF-α.

The invention discloses an early detection method for immune encephalopathy based on serum marker detection, and relates to the technical field of medical laboratory science, and the early detection method comprises the following steps: screening antigen epitopes by using technologies such as proteomics, constructing a phage antibody library, carrying out panning and mutation to obtain a specific antibody, constructing a nucleic acid library, screening and treating nucleic acid aptamers, and carrying out quantitative analysis on the nucleic acid aptamers. The preparation method comprises the following steps: synthesizing nanogold and magnetic nanoparticles by adopting a reduction method and a coprecipitation method, modifying a nanomaterial to obtain a compound, mixing the compound to form a probe, and optimizing a detection system to complete preparation. A bacteriophage antibody library is constructed, and an antibody with strong specificity and high affinity is prepared through multiple rounds of panning and site-directed mutagenesis optimization, so that the problems of poor specificity and poor sample enrichment effect of a detection reagent in the prior art are effectively solved, the detection sensitivity and specificity are remarkably improved, and early low-concentration markers of immune encephalopathy can be accurately detected.

The present invention belongs to the fields of genetic engineering and protein engineering, and specifically relates to a fully human antagonistic antibody targeting the PARP9 protein and its application. The present invention screens a fully human antagonistic antibody targeting the PARP9 protein from a human scFv phage antibody library, wherein the amino acid sequence of the antibody is as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The fully human antagonistic antibody has specificity for targeting the PARP9 protein and has potential application in the preparation of products for diagnosing, treating, or alleviating primary Sjögren's syndrome.

This invention discloses a shark-derived nanobody targeting the SARS-CoV-2 RBD protein and its applications. The nanobody's nucleotide sequence is shown in SEQ ID NO: 1, and its amino acid sequence is shown in SEQ ID NO: 5. Preparation involves immunizing a striped bamboo shark with the RBD protein, extracting total RNA from peripheral blood lymphocytes and reverse transcribing it into cDNA. The amplified VNAR fragment is then seamlessly ligated with amplified pR2 phage particles, transformed into TG1 competent cells, and a phage antibody library is constructed. SARS-CoV-2 RBD protein-specific nanobody sequences are screened from the library and recombinantly expressed to obtain the targeted shark-derived nanobody. The nanobody of this invention has a small molecular weight, allowing for the detection of the SARS-CoV-2 RBD antigen using paired nanobodies. It can be applied to immunoblotting, enzyme-linked immunosorbent assays (ELISA), and COVID-19 pharmaceutical applications related to the SARS-CoV-2 RBD protein.

The utility model relates to the technical field of bacteriophage culture and separation, in particular to a bacteriophage antibody separation and purification device, which is characterized in that when the bacteriophage antibody separation and purification device is used, bacteriophage and mixed liquid are poured into a stirring tank, and a stirring component is started, so that the stirring component stirs the bacteriophage and the mixed liquid in the horizontal direction and in the vertical direction simultaneously; when the inner side wall of the stirring tank needs to be cleaned, the washing assembly is operated to wash the inner side wall of the stirring tank, after stirring is completed, mixed liquid is discharged through the liquid discharging assembly, and convenience is improved; comprising a stirring tank and supporting legs, the multiple sets of supporting legs are installed at the bottom end of the stirring tank, the stirring device further comprises a liquid discharging assembly, a stirring assembly and a flushing assembly, the stirring assembly is arranged in the stirring tank, the flushing assembly is installed on the stirring tank, and the liquid discharging assembly is installed on the stirring tank.

The application discloses a shark-derived single-domain antibody binding SARS-CoV-2 RBD, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO: 2 or SEQ ID NO: 4; nucleotides encoding the above-mentioned shark-derived single-domain antibody, characterized in that the nucleotide sequence is shown as SEQ ID NO: 1 or SEQ ID NO: 3; the application also provides a preparation method of the shark-derived single-domain antibody binding SARS-CoV-2 RBD, and the shark-derived single-domain antibody is obtained by sequentially performing immunization, constructing a phage antibody library, screening positive clones from the phage antibody library, finally adding an inducer for expression after large-scale culture, and collecting and purifying antibody proteins; the shark-derived single-domain antibody prepared by the application has good application prospects in the development of a new coronavirus disinfecting spray and a new coronavirus antigen detection kit.

The present application discloses a use of an anti-adrenomedullin (ADM) antibody in the preparation of a drug for preventing or treating cerebral stroke. The antibody or a fragment thereof specifically binds to the first to twenty-first amino acid sequences of the N-terminus of human ADM, the first to twenty-first amino acid sequences of the N-terminus of the human ADM are as shown in SEQ ID NO: 2, and the monoclonal antibody or the fragment exhibits an affinity for ADM with a KD value of less than 10-10M. In the present disclosure, an anti-ADM monoclonal antibody is screened for by the hybridoma technology, and by means of humanization and expression of the antibody and panning of a fully human single-stranded phage antibody library, a fully human anti-ADM monoclonal antibody is obtained. On this basis, in the present application, the activity of higher binding to the N-terminus of human ADM is ultimately obtained by screening an affinity maturation library. The anti-ADM non-neutralizing antibody of the present application can be used in the development of a drug for preventing or treating cerebral stroke.

The present invention provides an anti-FAP nanobody, which includes complementary determining regions (CDRs) and framework regions (FRs); wherein the complementary determining regions (CDRs) include complementary determining regions (CDR1-CDR3); and the framework regions (FRs) include framework regions (FR1-FR28). The present invention successfully constructed an alpaca phage antibody library immunized with the extracellular segment protein of human FAP, and screened out 7 new anti-FAP nanobody VHH sequences from it. The nanobody sequence can recognize both human FAP antigens and mouse FAP antigens. At the same time, the nanobody sequence can be prepared into chimeric antigen receptor T cells (CAR-T) and can effectively kill cells that highly express human or mouse FAP. Therefore, it has the prospect of being applied to immunotherapy targeting FAP-positive cells, including tumors and fibrotic diseases.

The invention relates to the technical field of antibody screening equipment, in particular to precise antibody screening equipment for a phage antibody library, which comprises an equipment shell, a screening assembly is mounted in the equipment shell, the screening assembly comprises a mixing barrel, a stirring rod is rotatably mounted in the mixing barrel, one end of the stirring rod is connected with a blocking block, and the other end of the stirring rod is connected with a connecting rod. A one-way gear set is installed at the other end of the stirring rod, a rotating rod is connected to one end of the one-way gear set, a centrifugal barrel is installed at the lower end of the rotating rod in a transmission mode, a water pump is fixedly installed in the centrifugal barrel, and an auxiliary assembly is installed on the equipment shell; a constructor is externally connected with an air conditioner through a first spiral pipe access port, cold air surrounds the outside of the centrifugal barrel through the first spiral pipe and then is discharged through an adjusting pipeline and a first multi-way pipe, the centrifugal barrel absorbs the cold air for cooling, the temperature is maintained within a certain range, and the situation that phage particles are disintegrated due to the too high centrifugal temperature is avoided; the antibody display and screening results are influenced.

The invention belongs to the technical field of biology, and particularly relates to a phage vector, a construction method and application of the phage vector in construction of a high-titer and high-insertion-rate phage antibody library. The phagocytosis vector comprises a functional region and a non-functional region, the functional region comprises multiple cloning sites, the multiple cloning sites comprise single-type restriction enzyme cutting sites, and the restriction enzyme cutting sites are used for connecting a target gene sequence. The construction of the single-enzyme digestion phage plasmid vector and the phage library constructed by the single-enzyme digestion phage plasmid vector have the advantages that the insertion rate of gene fragments is higher, the storage capacity is higher, the titer reaches 1010 cfu / mL, and the optimized single-enzyme digestion system is more suitable for construction of the phage library than a double-enzyme digestion system.

The invention belongs to the technical field of biology, and particularly relates to a screening method of an anti-AEP specific nano antibody phage, which comprises the following steps: S1, immunizing a target animal by using an AEP antigen composition to obtain cDNA (complementary deoxyribonucleic acid); s2, amplifying a nucleotide fragment of VHH of AEP from the cDNA; s3, preparing a single type of restriction enzyme cutting site-VHH gene; s4, connecting the single-type restriction enzyme cutting site-VHH gene to a phagocytosis vector to obtain a recombinant phagocytosis vector; the phagocytosis vector comprises a functional region and a non-functional region, the functional region comprises a restriction enzyme cutting site, and the restriction enzyme cutting site is a restriction enzyme cutting site of a single type; s5, transforming the recombinant phagocytosis vector into a host cell to obtain a transformed cell; s6, infecting the transformed cells with auxiliary bacteriophages, and culturing to obtain a bacteriophage antibody library; and S7, screening the phage antibody library to obtain the anti-AEP nano antibody phage. According to the method, the obtaining efficiency and screening specificity of the nano antibody are improved, and non-specific interference in the experiment process is reduced.

The present invention belongs to the technical field of antibody preparation, and specifically relates to an anti-African swine fever virus antibody targeting p72 protein. The antibody belongs to a single-chain antibody that only includes a heavy chain variable region VH and a light chain variable region VL. In the present application, based on the existing mature phage antibody library screening technology, a specific scFv-Fc antibody with high affinity for the African swine fever virus capsid protein p72 protein was screened and obtained. Preliminary experimental results show that the single-chain antibody better retains the affinity activity for the antigen, can specifically recognize and bind to the capsid protein p72; and because of its small molecular weight and strong penetrating power, it is easy to prepare in large quantities through genetic engineering technology with the help of prokaryotic or eukaryotic expression systems, which can lay a certain technical foundation for the development of drugs for the detection, prevention and treatment of African swine fever virus.

The present invention belongs to the technical field of biomedicine, and provides an anti-TIF1-γ monoclonal antibody and its application. The present invention uses phage antibody library technology to screen out a human-derived anti-TIF1-γ monoclonal antibody with good specificity and strong affinity. By specifically binding to TIF1-γ, the antibody can quantitatively detect the level of anti-TIF1-γ autoantibodies in DM patients, thereby monitoring the disease activity, and can be used for the clinical diagnosis of DM patients. The research of the present invention provides a theoretical and experimental basis for the specific treatment of DM, and also provides a new research direction for the treatment of autoimmune diseases with autoantibodies as the main pathogenic mechanism.

The invention belongs to the technical field of biological medicine, and provides an anti-TIF1-gamma monoclonal antibody and application thereof.The human-derived anti-TIF1-gamma monoclonal antibody good in specificity and high in affinity is screened out through a phage antibody library technology, the antibody is specifically combined with TIF1-gamma, and the TIF1-gamma monoclonal antibody with high affinity is obtained. The anti-TIF1-gamma autoantibody level in a DM patient can be quantitatively detected, so that the illness state activity degree is monitored, and the kit can be used for clinical diagnosis of the DM patient. The research of the invention provides theoretical and experimental basis for specific treatment of DM, and also provides a new research direction for treatment of autoimmune diseases with autoantibodies as main pathogenic mechanisms.

The application provides an anti-alanyl-tRNA synthetase single-chain antibody and a preparation method thereof, the anti-alanyl-tRNA synthetase single-chain antibody comprises a heavy chain variable region and a light chain variable region, the DNA sequence of the heavy chain variable region is shown as SEQ ID NO:1, and the DNA sequence of the light chain variable region is shown as SEQ ID NO:2. After healthy mice are immunized by using the antigen prepared in the laboratory, the antibody titer is qualified, the spleen is taken to extract RNA, and the ScFv is obtained through the modes of RT-PCR, PCR and overlap extension PCR; after being connected with a pCANTAB5e vector, phage antibody library is obtained through electric transformation; through multiple rounds of screening, the antibody sequence with high titer is obtained; the application has the advantages of large antibody library capacity, relatively simple operation, low cost and the like, lays a foundation for further application in an in-vitro diagnostic kit, and has a wide application prospect.